Sign up to save your podcasts
Or
Share Compass trials mark a milestone moment for the psychedelics sector
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Compass trials mark a milestone moment for the psychedelics sector
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.
View all episodes
By RBC Capital Markets
5
1212 ratings
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,234 Listeners
WSJ Your Money Briefing
1,724 Listeners
Exchanges
962 Listeners
Odd Lots
1,986 Listeners
WSJ Tech News Briefing
1,655 Listeners
The a16z Show
1,094 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
334 Listeners
Wall Street Breakfast
1,051 Listeners
Thoughts on the Market
1,301 Listeners
The Journal.
6,083 Listeners
BioCentury This Week
35 Listeners
RBC's Markets in Motion
41 Listeners
Biotech Hangout
21 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
The Markets
76 Listeners
Strategic Alternatives
17 Listeners
The Top Line
16 Listeners
Macro Minutes
3 Listeners